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Unstable angina pectoris i  a syndrome of ischemic heart 
disease that is associated with a high risk of sudden death, 
myowdial infarction and persisting angina pcttis (l-3). 
Current medical therapy includes administration of itrates. 
beta-adrenergic hl&ing agent8 and calcium channel ant&? 
onists (4-6) and aspirin or heparin (7- IO). There is evidence 
that transient lhmmbotic obstruction contributes to the 
clinical syndnwe (11-13). A primary role cf platelets in 
coronary artery occlusion has been doeumeoted (14-20). 
and thrombin has been shown to play a pivotal role in 
platelet-mediated rterial thrombosis (21-24). In addition. 
synthetic thrombin i hibitors are significantly more potent 
than heparin i preventing platelet-mediated rterial throm- 
basis in viva (21-24). We have previously studied tk 
relative efficacy ofh&n and of the synthetic competitive 
thramhin hibitor. qatmban. (2R. 4R)-4-methyI-l-IN*-(3- 
~thyl-l,2,3,4-tet~yd~ahydro-&quinesu~onyl~~~~~nyll-2- 
piperidinecarboxylic acid monohydrate. in preventing 
ok&let-rich arterial thrombosis in a rabbit femoral anew 
iversion graft model (24). At a dose that prolonged thk 
activated oanial thrombuolastin time (am) to a com- 
parable exient. the syntheiic thrombin inhibitor was signifi- 
cantly more efficient than was heparin for the prevention 
of platelet-rich arterial occlusion. 
Argatrobaa has previously been administered to patients 
after cardiovascular surgery or with intravascular coagula- 
tion (25) and in association with hemodialysis (26). Infusion 
rates of 0.7 to 5.0 &kg per min were well tolerated and 
resulted in a IS- to 3.fold prolongation of apIT. More 
recently, tbe pharmacodynamic r-oprties of low dose arga- 
troban, alone and in combination with aspirin, have been 
studied in healthy volunteers (27). Argatroban was found to 
induce a dose-dependent prolongation of aplT that was not 
influenced by aspirin. 
la the present study, a 4-h intravenous infusion of arga. 
troban in doses ranging from 0.5 to 5.0 &kg per min was 
administered to patients with unstable angina pectoris. The 
antithrombotic effects of treatment were evaluated during 
infusion and at 2 h after infusion by sequential measurements 
ofthe plasma concentrations of 1) fibrinopeptide A, a marker 
of thrombin activity toward fibrinogen, and 2) thrombin- 
antithrombin III complex, the quantity of free thrombin 
inhibited by antithmmbin III. Patients were also monitored 
clinically for signs of recurrent ischemra during the next 24 h. 
Methods 
Study patknts. Fifty patients with a clinical diagnosis of 
unstable angina pectoris who were admitted to the Cardiac 
Unit of the Massachusetts General Hosoital for diaanostic 
coronary angiography were considered’for entry imo the 
study. These patients were treated with a standardized 
anti-ischemic regimen, as tolerated, consisting of nitrates 
(isosorbide dinitrate, 30 mglday orally or nitroglycerin, 50 to 
400 mglday intravenously); orally administered beta- 
adrenergic blocking agents (propranolol, 40 to I60 mglday: 
atenolol, 50 to I00 mglday, or metoprolol, 100 to 
200 mglday); calcium antagonists (nifedipine. 40 to 
I20 m!Jday: or diltiazem. 120 to 360 mg!day) and aspirin (I&l 
or 325 mglday) or intravenous heparin, or both. Other drugs, 
including digitalis. diuretic drum. antihvoertensive aaeats. 
antiatiythmic drugs, oxygen aid sedatives, were adminis- 
tered as needed. To qualify for entry into the study, the 
patients had to fulfill the following criteria: I) at least one 
episode of chest pain at rest for ~30 min within the previous 
6 days associated with reversible electrocardiographic 
(ECG) ST segmeut or T wave abnormalities, or both, com- 
patible with ischemic coronary artery disease; 2) XXJ% 
diameter stenosis in the ischemia-related coronary artery, as 
documented angiographically; and 3) age between 21 and 76 
years. 
Exclusion criteria were myocardial infarction (pain for 
>30 min or new ST-segment elevation ~0.1 mV in two or 
more contiguous leads, or both, refractory to nitmglycerin 
administrationl, left bundle branch black, acute uulmunarv 
edema. hepatic disease, renal failure. child-be&g poten- 
tial, hvwtension (<Xl mm Ha), suraerv within the orevious 
8 weeks, tbrombolytic therapy within the previo& 48 h. 
platelet couut <llHI,ONJ/mm’, active bleeding, prolonged 
template bleeding time, peroral anticoagulation or a history 
of a bleeding diathesis. 
When included in previous treatment, aspirin was with- 
held between entry into the study immediately after carp 
nary angiography (I8 to 24 h before argatroban infusion) and 
the 24-h observation period after cessation of argatroban 
infusion. This decision was based on the observation by 
Thdroux et al. (9) that in patients with unstable angina &her 
aspirin or heparin treatment was associated with a reduced 
incidence of myocardial infarction, with a trend favoring 
heparin over aspirin. whereas the combination of aspirin and 
heparin had no greater protective effect than that of hepwin 
alone but was associated with slightly more serious bleeding. 
All patients had been referred by their physician for 
diagnostic coronary and left ventricular angiography. per- 
formed by the Judkins technique after standard heoariniza- 
tion (5,0&l U bolus iutravenou;ly), I8 to 24 h beforeSiufusion 
of the study drug. In patients without augiographically 
visible thmmbus, no further heparin was administered. In 
I8 patients with angiographic evidence suggestive of intralu- 
minal thrombus, a constant intravenous hepmin infusion 
(1 ,ooO U/h) was continued until approximately 4 h before the 
scheduled time of argatroban infusion. Before initiation of 
the study drug. the aPlT was documented to have returned 
to ~40 s. Guidelines for reinstitution of heparin during the 
24-h follow-up period after cessation of argatroban infusion 
included the recurrence of ischemic pain (seven patients) or 
a return of the aPTT to nonal values in patients with clear 
evidence of inttaluminal tilling defects in the ixhemia- 
related artery on coronary an&raphy or with a 295% 
coronary artery stenosis (eight patients). In all other pa- 
tients, heparin and aspirin administration was withheld until 
24 h after the argatrobau infusion. when the study was 
considered to have been completed. 
Three eligible patientr were not entered into the study 
phy. Four &hers were &en argatroban beiausi 
had a cardiac ischemic event in the I8 to 24 h between 
an&raphy and initiation of argatrohan infusion (acute 
myofardial infarction in two and severe unstable angina 
requiring angioplasty in the other two despite continued 
heparin infusion). 
Angiugrapidc awlyl. Augiographic analysis was per- 
formed by two experienced cardiologists who had no knowl- 
edge of the patients’ treatment. The coronary artery supply- 
ing the ischemic zone was prhuarilv identified bv the ECG 
k&ion of reversible ST s&ent ch&ges during;hert pain. 
In patients with single-vessel disease, the stenotic artery was 
assumed to be the ischeruia-related artery. In patients with 
multivessel disease, the ixhemia-related artery was identi- 
fied by correlating the ECG changes with a correspoudmg 
segmental wall motion abnormaliry on left ventriculognphy 
or gated blood pool scan. In patiects with multiple srg- 
mental well motion abnormalities or normal wall motion, the 
ischemia-related artery WBE identified by the zone ofthallium 
redistribution or. if that was not available. by the location of 
ECG changes. 
Qoehtative analysis of the lesion in rhe &hernia-related 
tiery was performed by the method of Ambrose et al. (28). 
which classifies lesions es concenuic (symmetric “anow- 
iog), type I eccentric (asymmetric “arrowing with smooth 
barders and a broad neck), type It eccentric (asymmetric 
with a “mow neck or irregular borders or both), 0; multiple 
irregular narmwings. In addition, en attempt was made to 
identify intracoronary thrombus, which was defined es a 
filling defect occuning at the site of e stenosis, surrounded 
by contrest medium on et least three sides and visualized in 
multiple views. 
Coronary stenosis was measured quantitatively by a” 
automated Spa-based computer system that yields ” root- 
meatt-square c?ror of O.tXX- mm a. phantom- vessels and 
con&des with micrometer I = 0.999 lDieitel Analvsis 
System, United Cerdiec Systems). Views ofthe stendsis. 
adjacent normal reference end catheter tip were optically 
magnified 4 times. digitized and dieitaUv mannitied to “tote! 
of 8 times. Borders were deteroikd 6y “&we modeling 
discti”ti”e”t analysis, and diieten were automatically 
computed perpe”diculaly to the centerline for each seg- 
ment. Measurements were calibrated to millimeters based on 
catheter tip diameter. These data were collected without 
lolowledge of the study drug M clinical course of the 
patients. 
SMY dw admMshntitm. After baseline mewremem 
of vital sigm aad blood senvlinn for routine laboratory tests 
end hem&& analyses, &i&i” was i”fused i&we- 
PIOUSLY (200 ml total volume) by meeos of a constant rate 
infusion pump. A dose of 0.5 &kg per min for 4 h was 
initially s&c~ed, and subwque”; &r&e”t groups of four or 
live patients each were assigned consecutively to dosage 
regimens ‘&eased by increments of 0.5 &g per min. The 
maximally tolerated dose wes prospectively detenined as 
the dose immedietelv mwedine that a! which the infusion of 
drug wee terminated &cause he significant cliDicel event 
other the” angina pectoris or at which the pmthromhi” time 
or the activated partial thmmboplastin time measured three 
times the upper limit of normal in two patients &ted to that 
dosage group. It was prospectively determined that the 
infusion would be terminated in individual patients if pro- 
thmmhi” time or ePlT prolongetion exceeded three times 
the upper limit of normal. bleeding time pmlongation ex- 
ceeded three times the upper limit of normal, clinically 
signIEcaot bleeding oaurred or signiicant coronary isch- 
emia was observed (“one of these end points actually 
occwred). In one patient who received a dose of 2 &kg per 
mi” for 4 h, argetroban was partially administered extravab 
cukuly tbrougl~ en intravenous cannola that had perforated 
the vein. After completion of the infusion, patients were 
closely monitored for the “ext 24 h for recurrent chest pain 
and associated ECG changes and responsiveness to subtin- 
gual nitroglyceria 
The study was conducted within the fmmework of a 
protocol approved by the Bureau of Biologics of the Food 
and Drug Administration and by our hospital subcoti~ee 
on human studies. Written informed consent waj obtained 
from all patients. The synthetic thrombii inhibiior (21, 
4R~-4-me~hyl-I-[N’-(3-methyl-l.2,3,4-tetrahyd~8qui”o- 
linesulfonyl).L-arginyll-2-piperidineear acid monahp 
drete (argatrobao) was provided by Genentech as a sterile 
isotonic solution in Mml vials coixaining 10 mg of active 
material. 
Coll&ion of blned stolples. Blood samples (4.S ml) for 
assay of aPlT. prothrombin time, thmmbin time, platelet 
cou”t, arachidonic acid (1 nunol/liter)_induced platelet eg- 
gregation (to document inhibition ofcycloaxygenase wtivity 
by aspirin). and plasma argatmban co”ce”&o” were co< 
lected into 0.5 mt (0.1 moljliter) sodium citrate. andforassev 
of libtinopeptide A and thmmhin-antithromhi~ III cornpI& 
into 0.5 ml fibrinopeptide A anticoagulant sol&o” 
(Mallinckmdl). These samples were obtained 5 mio before 
infusion of argatmbat, at midinfusion (2 h). immediately 
before the end of the infusion (4 h) and 2 h after comoletio” 
of the infusion. Template bleeding times were m&ared 
from a standardized sntecuhital incision (5 mm long by 1 mm 
deep) produced by ” spcing-activated se+el steel blade 
instrument (Surgicutt International. Baxter Medical Pmd- 
ucts) before ergetmban infusion, 3 h after the start of 
treatment and I h after ccrsation of infusion. 
Samples of free-flowing blood were routinely obtained 
from the amt contralateral to the argetmba” infusion 
through venous access established by a large bore (I8 geoge) 
2-i& (5 cm) ctmttula that was kept patent by a conti”uous 
infusion ofa5%solutionofdextmse inwater. At& lnidtial 
10 ml was obtained for coagokuion and plasma drug mea- 
surements. blood for fibrinopeptide A aad thmmbin- 
antithmmbin 111 complex measurement wes collected di- 
rectly inlo the anticnegolaot solution to inhibit thrombi” 
generation or throabin ectivity ia vitro. All samples were 
carefully mined. placed o” ice and cenaauged promptly et 
2.cHM g for I5 min. The platelet-poor ple.s”le for “leesure 
ment of eFTl’, pmthrombi” time and thmmbi” time was 
analyzed immedietely, and for assay of fibrinopeptide A and 
thrombin-antithmmbin III complex it wee stored at -7(pc 
until use. Additionally, in 1 I patients blocd samples were 
obtained by vei” ptmctore for determination of fibrinow- 
tide A and thrombi”a”tithmmbi” III complex levels before 
infusion of argetmb”n, immediately before the end of treat- 
ment and 2 h after the infusion had bee” completed. 
Lsbereton ays. The “te”suremem of eIlT (“Onoal 
range 25 to 30 s) &s performed on 0.1 n-d of citrated~pkasma 
incubated with 0.1 ml Kontact reaeent 1Pacitic Henmstasis) 
for 5 mi” at 31°C after rec&ic”tib” with 0.1 ml oi 
0.025 mokliter calcium chloride. The pmthmmbi” time (nor- 
mal range within 2 s of contml plasma) was deteirnined on 
0.1 ml of titrated plasma. prewarmed to 37°C by adding 0.2 
ml of thmmboplastin reagent (Pacific Hemostasisl, and the 
thmmbin time was measured with 0.2 ml of titrated plasma 
after addition of 0.1 ml Thrombinex (BialData). All of these 
assays were performed in a fibrometer. Fibrinopeptide A 
levels were measured usiiia a radioimmunoassay kit 
(Mallinckrodt) on plasma from which fibrinogen had-been 
absorbed with bentonite. Thmmbin-antithrombin III com- 
plex levels were measured with an enzyme-linked immu- 
nosorbent assay (Boehringer). Plasma levels of argatroban 
were assayed by high pressure liquid chromatography per- 
formed at Genentech, as dcscribad elsewhere (27). 
Slstislical analy&. Results were expressed as number of 
patients or as mean value i BD. 5adent f tests were used to 
evaluate diRerewes between groups of continuous data, and 
Fisher or K&xl-Wallis erect tests were used to evaluate 
differences between groups of categoric data. Significance 
levels are reported as twa-sided p values. Linear regression 
analysis was used to correlate dose of argatroban with 
steady state plasma argatroban level and with aPTT values 
and to correlate fibrinopeptide A levels with dose of arga- 
troban and with aPl’T values. 
The tibrinopeptide A (fpA), thrombin-antithrombin III 
complex (TAT) and steady state plasma argatruban (Arg) 
levels (in @ml) were not normally distributed es determined 
by the Wilk-Shapiro test of the RSI program (Research 
System 1, BBN Systems). Therefore, for statistical analysis, 
the data were expressed as In(IfpA1 + I), as In([TATl t I) or 
as ht([Arg?), which were normally distributed. Comparison 
of In([fpAl + I) and In([TATl + I) versus time and versus 
dose of argatroban were justified based on overall statistical 
significance demonstrated initially by factorial one-way anal- 
ysis of variance (ANOVA, BMDP Software, program P4V) 
(p < 0.01). This initial analysis of variance protected against 
multiple comparison giving false significance (Duncan’s pru- 
eedute) (29). 
Ulnical and anglagraphlt 8ndb?& The dewgraphic and 
clinical chamcterisrics of the patients are summarized in 
TaMe I. All patients had pa& with reversible ECG ST 
segment or T wave changes indicative of myocardial isch- 
emia within 6 days (mean t SD 3.5 c 1.9) before entry into 
the study. During this time, they were treated with beta- 
blockers, calcium channel antagonists, nitrates and aspirin 
or intravenous heparin (Table 1). Aspirin was withheld 
between entry into the study until 24 h after argatroban 
infusion. Heparb? was discontinued for 54 h before arga- 
troban infusion, which was initiated only aftet documented 
normalization of the aPM to <40 s. In IS patients, pmtucol- 
mandated heparin i fusion was reinstated within I?. h atIer 
the atgatroban infusion because of recurrent ischemia (n = 
7) or cicarly visible intracoronary thrombus or subtotal 
occlusion on coronary angiography (n = 8). 
all patients within 18 to 24 h before urgatroban infusion, are 
summarized in Table 2. Fur the total muup, the mean 
number of steuosed vessels was 1.9 ? 0.8, and the culprit 
lesion was located iu the following arteries: left anterior 
descending coronary artery in 19. rlgbt coronary artery in 12, 
left circumtkx carunxy artery in 8, left main euronary 
artery in I patient and a coronary artery bypass graft in 3 
uetients. The uercent diameter stenosis of the culmii lesion 
was 84 r 12%: and I5 patients had angiagruphic evidence of 
intracaroaary thrombus. 
Pharmaemlyaamks uf asxatmbau. The argatrobaa infu- 
sion was completed in all 43 patients given this drug. No 
clinical hleedina occurred durine or within 24 h after cessa- 
tion of the i&on, and no myocardial ischemic event was 
recorded during the infusion. No other adverse effects or 
changes in the routine hematolugic or blood chemistry 
variables were observed (data not shown). 
Table 3 summarizes the results of aPIT. bleedinn time. 
plasma levels of argatroban, Cbtinopeptide A and thGmbin_ 
antithrombin III complex assays. For display purposes, 
p&eat groups are combined in three clusters, receiving 
I) 0.5, I.0 or 1.5; 2) 2.0, 2.5 or 3.0; or 3) 3.5, 4.0, 4.5 or 
5.0 &kg per min 0;’ argatroban. However, statistical anal- 
ysis was performed on individual patient data. lnttavenws 
infusion of argalroban produced a dose-related prolongation 
of aplT (I = 0.65, P = O.ooOl, n = 41) and a dose-related 
increase in the steady state plasma levels of the drug (r = 
0.84, P = O.OCa31, n = 40) but had no effect on the template 
bleeding time. A two-fold or greater increase of aFlT over 
baseline values was obtained at an infusion tate ~2 to 
3 /&kg per mitt of argdtin, resulting in a steady state 
plasma concenlration 20.7 f 0.3 Irglml. 
The baseline levels of fibrinopepride A (geometric mean 
20 nglml with 95% conlidence iniekal of ISio 23 nglml) arid 
of thrombin-antithrombin III comulex (4.2 w/ml with 95% 
confidence interval of 3.0 to 5.8 &tnli we;3 to IO times 
higher thae nunnal values (<2 nglmi for fibrinopcptkle A (30) 
and I.5 &ml for thrombinantithmmbin III complex (infor- 
mation supplied with the reagent kit), During argatroban 
infusion, the (nonlogarithmic) concentrations of fibtinopcp 
tide A decreased 2.3.fold (P = 0.031 vs. baseline). hut no 
signilkant change in throhbin-antithrumbin Il1 .compkx 
from baseline values was observed. 
Two hours after compktion of infusion, the aFll’ had 
returned toward baseline-in the low dose cluster groups but 
remained I.3 + 0.3 and 1.4 i: 0.3~fold molonaed in the . _ 
medium and high dose clusters, respectively. Residual 
plasma argatroban levels were approximately IS% of the 
steady state plasma level, consistent with a half-life of 30 to 
45 min. At that time, however, a significant 3.sfold (non- 
luwithmic) increase over oretreatment values in the ulasma 
thrombin-antithmmbin Ill~complex concentration w& nrea- 
wed (p = 0.002). whereas librlDcpeptide A levels, sup 
pressed dutinainfusion. increased sianificantlv. aoaroachinn 
ihe previoual~ elevated baseline l&Is (p < i.odli. _ 













both from the indwelling catheter and by vein puncture, the 
tibrinopeptide A levels, expressed as geometric mean with 
(9% confidence interval), were 29 (21 to 40) and 6. I (3.4 to 
10) @ml at baseline, IOG.2 to 19) and 1.9(1.1103.2) nglnd 
at 4 h and 19 (6.2 to 55) and 3.3 (1.9 to 5.3) ng/ml at 6 h. 
respectively. The values obtained on samples from the 
indwelling catheter were indistinguishable from those in the 
total group, whereas those obtai&d by repeated vein punc- 
ture were significantly lower than those obtained from the 
catheter (p < 0.04 at each time point). 
Ia the patients with blood samples obtained by direct 
vein rmncture. amatrobsn infusion caused a sianificant 
3.2-foid (nonlogari;hmic) decrease in fibrinapeptide_A levels 
durinr: infusion (D < 0.03) with a I.Tfold increase within 2 h 
atIer &s&n 0; the infusion (p = 0.17 vs. baxline). 
Inspection of the rw data of fihrinopeptide A and 
thmmbin-antithmmbin 111 complex assays revealed some 
heterogeneily in the response :o argatian inCusion. Of the 
30 &Wients with a complete set of hbrinopeptide A values, 7 
showed a persistent twofold M greater fibrinopeplide A 
reduction during and after infusion, 15 displayed a suppres- 
sion during infusion with a twofold or greater increase after 
cessation of inlusion, whereas 8 patients had a variable 
response. Thnxnbin-antithmmbin If1 complex levels in- 
creased at least twofold over end-infusion values within 2 h 
after the end of the infusion in 23 of the 43 patients. and in I9 
of these the 6-h thmmbin-antithmmbin 111 ~;omple.x level was 
at least two times higher than the baseline value. 
Mvwwdial h&mic ercat+ Nine Patients developed an 
episode of unstable angina within Ski + 2.6 h after the 
cessation of amatmban infusion (3.8 + 2.6 h after normal- 
ization of aFt%, which in two patients evolved to acute 
myocardial infarction In these nine patients, the pain epi- 
sode was associated with reversible ischemic EC0 changes 
in six, l&bundle branch block inoneand no reversible ECG 
changes in two. AU nine patients with pain responded 
pmmptly to relief of discomfmi with administration of 
sublingual nitroglycerin. 
Table 2. Aegogmphic Chamcreristics of the Study Parientr 
-_____ 
The 9 patients who developed early recurrence of angina 
were indistinguishable from the other 34 patients entered 
into the study with respect to demographic characteristics, 
severity or timing of the qualiiying anginal event, and 
antianginal or anticoagulant medication (Table I). F~tocol- 
driven reinstitution of heparin within 24 h was more frequent 
in the patient group demonstrating recurrent ischemic symp 
tams within 24 h after cessation of argatroban infusion than 
in the group without early angina. Patients with or without 
recurrent angina were also similar with respect to coronary 
angiographic characteristics including the number of 
coronary vessels with rS%% stenosis, the distribution of 
ischemia-related arteries, the degree of stenosis, the mar- 
phology of the culprit lesion and the presence or absence of 
intracoronary tbmmbus (Table 2). The thrombin-antilhrom. 
bin III complex and fibrinopeptide A levels at baseline, 
during infusion and 2 h after infusion of argatroban were not 
signiticantly different between patients with and without 
recurrentangina(Table 4). However, patients with recurrent 
angina received a significantly higher dose of a@roban 
(Table I), and had significantly higher steady state plasma 
argatrohan levels and significantly greater prolongation of 
the aFTT than did patients without this symptom (Table 4). 
Discussion 
Several clinical and pathologic studies (31.32) have dem- 
onstrated that atheromatous plaque rupture with mural or 
occlusive coronary artery thrombosis plays a major role in 
the development of unstable angina pectoris or ewte myo- 
cerdiai infarction. Interventional studies have ;cmested that 
the owcome of patients with wstable angina may be im- 
proved by administration of aspirin or heparin, or both (7-9). 
but this treatment is not uniformlv successful. Swcit!c 
thmmbin inhibitors, including trip&de chlorome&l ke- 
tones (21). hirudin (22) or araatroban (24.331. are more 
potent than heparin ior ;he p&ention oiplateikt-mediated 
ertenal ttuombosis. Accordingly, such agents may consti- 
tute alternative end more potent approaches to the treatment 
of unstable cornnary syndromes, thus providing the ratio- 
nale for the current investigation. Proposed mechanisms 
explainina the superiority of synthetic thrombin inhibitors 
over hep& for ihe pr&ention of tie& thrombosis in- 
clude better local inactivation of thrombus-associated 
thrombin, more efficient ichibition of meizothrombin, which 
is resistant to the heparln-antithrombin III complex, and 
more efficient diffusion of the low molecular weight inhibi- 
tors into the thrombus (21). 
pbumrad~ia ef ergatmbee. The present study 
confirms and extends to patients with unstable angina pec- 
tods previous observations (25-n) that argatmbatt has no 
adverse effects during intmvetmus infusion in humans at the 
selected infusion rates and pmdwes dose-related prolong 
tion of the apIT, indicative of clotting nhibition. Effects on 
hemostasis as delineated by thrombin activity toward fibrin- 
ogen (tibrinopzptia A concentrations) or the amount of 
f&e thrombin &mplexed by circulating antithrombin Ill 
fthrombinantitbrombin 111 comolex concenlrationsl have 
not beer, previously documanted~ 
lnenased plasma fibrinopeplida A levels documented ia 
patients with unstable angina pectoris substantiie ongoing 
pmcoagulard activily and activatti of the coagulation 
&h&ism (34). In-our patients argatrobw pro&ced a 
U-fold reduction of elevated baseline fihrhtopeptidc A 
levels. However, in viva thromhin generation wa9~s&ained, 
es evidenced by no significant change in the ovemll plasma 
concentration of thmmbin.antithromhin 111 complex during 
wgatroban infusion even at the biiest doses. 
The rapid reduction of fibrinopaptide A levels during 
tugatroban infusion is consistem with the 3 IO Smht plasma 
haWe oflhe peptide (M), which allows a rapid response to 
anticoagulation. The plasma half-lie of thmmbiwmtithmm- 
bin 111 complex is less well deftned because values ranglog 
between 5 min and 12 h have bean reported in animal models 
(35.36). The most probable value for the half-life of thmm- 
bibantithrombin 111 complex in humans, obtained from 
autoloaous tbrombm-antithmmbin III complex traasfusian 
cxpari~ents, appears to be IS min (Rosanb& R, Massachu- 
setts Institute of Technology, Cambridge, pcrroaal commu- 
nication). The persistence of elevated thmmtinwdithmtw 
bin III complex levels during argatmbsn intitrmn tlwefore 
would he indicative of continuing in viva thrcmbin genera- 
tion during bdwion of the thrombin inhibitor. 
cbar&~ristics et the rebound WSgiol. sm-prisblgly. ces- 
satiou df argatroban infusion was associated with early 
recurrence of rest angina in 9 of the 43 patients. The patients 
with and without early angina were indistinguishable by 
demographic, clinical or laboratory variables. Detailed COT- 
anary angiographic analysis demonstrated similar character- 
istics bctwecn the two group, indicating that recurrent 
angina was not associated with ditTerences in the nature and 
severity of the underlying coronary anatomy and, poten- 
tially, of coronary pmcoagtdant activity. However, a highly 
significant correlatiin was observed between early recur- 
rem of angina and the dose of agatmban and between 
early angina and the aFTf prolongation. Although a selec- 
tion bias cannot be excluded becaw of our ttonrandctmized 
study design, the high cwrelation between the ocWKellce of 
angina and the dose of argatmban in the absence of a 
significant correlation with any cf a large number of other 
variables (Tables I, 2 and 4) argues against this possibility. 
Cessation of infttsicawaswaaciated withareboundincrease 
of (nonlogaritbmic) thrombin-antitbmmbin III complex lev- 
els within 2 h to levels sigrdftcantly above baseline and an 
increase of the suppressed librinopeptide A levels toward 
or&fusion values. tmtwithstandiw a low demee cf residual 
kicoagulant (1.1: to 1.4.fold aPl% pmlon&on) e&t cf 
persisting argatmban at that time. Measurement of fibrin- 
opeptide A levels was routinely performed on blood samples 
obtained from indwelling catheters, which yielded signili- 
cantly higher levels than those of assays on samples obtained 
by vein puncture. However. a propartionatly similar reduc- 
tion of fibrinopeptide A concentrations during %gatr&an 
infusion and a similar increase after the end of the infusion 
were observed in a subgroup of II patients in whom bled 
was also obtained by repeated vein puncture. 
The occurrence of the clinical syndrome after such a 
short-lemt infusion of argatroban and its relation to the dose 
and auticoagulanl effects of the study drug suggest that it 
repre~ nts a flue rebound phenomenon and not a reappear- 
ance cf symptoms after disappearance of the protective 
effect af argatroban from the blood. Its association with 
biochemical evidence of rebound thmmbin generation in 
viva fihemmre suggests that it may be directly linked to 
increased activation of the coagulation cascade aCter the 
disappearance of antithrombin activity from blood. 
Fiienthd lhilaliom of the study. Our results require 
intemretation with several limitations in mind. As con- 
ceived, designed and wnductcd, the current study consti- 
tuted a Phase 1 investigation of the safety and pharmacody- 
M&S of escalated dosage regimens of wgalmban. Patients 
with unstable angina pectoris potentially comprised a c&e- 
gory of persons who could benefit from therapeutic applica- 
tion of selective thrombin inhibition. However, this investi- 
gation was not designed to pmspectively test the efficacy of 
therapy, alone or in comparison with conventional anticoag- 
ulant (heparin) or placebo-allowed treatment groups, or 
even to address the rebound phenomenon, and therefore was 
not controlled by a randomized, blinded design. Thus, 
potential bias &h respect lo patient seleftiohand data 
colkction and analysis cannot be excluded. These shortcom- 
ings rexpdre that the rebound phenomenon he cantimxd and 
further characterized in a prospective study design. 
Nevertheless, the high frequency of recutwtt angina and 
the biochemical evidence of coagulation system activation 
atIer cessation of argatroban infusion represent striking and 
surprising observations. Although they need lo be evaluated 
for~their~therapeutic consequences in a prospective study 
design, these data may be of signiRcance for the use dthese 
agents in humans. The rectuwce of unstable angina aCter 
selective thrombin inhibition in our study is similar to results 
of the recent clinical studv bv Thdroux et al. (37) document- . _ 
ing reactivation of unstable angina after cessation of heparin 
infusion. 
The present study focuses on the potential link between 
clinical recurrence of angina and biochemical evidence of 
increased thrombin generation. Table 3 suggests that the 
hugest increase in Ubrinopeptide A levels after cessation of 
argatroban infusion is observed in the lowest dose groups, 
whereas the frequency of early recurrence of angina is 
correlated with the dose of argatmban. This apparent pam- 
dox may be explained by the persistence of anticoagulant 
activity in the highest dose groups (aFTI 1.4 times baseline), 
which may have delayed the occurrence of rebound coagw 
lation in the hiahest dose arows after the bload sam~lina 
period. Fibrinopeptide A I& increased above p&a~ 
menl values have also been r+rved after discontinuation of 
heparin in patients with acute myocardkd infarction (38) and 
during thmmbolytic therapy in patients given no or insufli- 
cient hepari” (39). 
Administration of heparin and aspirin, alone or in combi- 
nation, widely used in treating unstable angina pectoris, 
poteatiatty confounds our evaluation oi the selective etTec,s 
of argatraban infusion. Although aspirin use was discontin- 
ued in the present study 18 to 24 h before argatroban 
intusion, inhibition of cyclooxygenase activity would never- 
theless wxsist for an additional I to 10 davs, an effect 
comitm~d by the blockade of arachidonic &-induced 
platelet a&alion in the 14 aspirin-treated patients CTable 
I). Althouah no sianiticant diierences in aspirin intake and 
inhibition if wachidonic acid-induced plat&t aggregation 
were observed between patients with and without recurrent 
at&a. we cannot exclude the possibility that aspirin pro- 
tected against recurrent angina (37). thus decreasing the 
overall Creouencv of this svnwtom in our study. Clinical and 
hemostaticSeffecis of hepa&administtation before or after 
argatroban infusion must also be considered. No significant 
differences in coronary angiographic characteristics (with 
the exception of intracoroaary thmmhus) were observed 
between patients with and without reinstitution of heparin 
within 12 h aRer cessation of atwtroban infusion. Thus, 
anticoagulant therapy was not readministered selectively on 
the basis of knowledge of underlying coronary anatomy in 
uatients who may have bem at increased risk of ischemia. 
The causativ; role of platelets and thromboxane release 
in unstable angina has been elegantly demonstrated in clin- 
ical studies by Hinh et at. (40) aad by Fiirdtd et al. (20). 
In the cm-rem investigation. the apparent overall similarity 
of fibrinoocotide A and tbmmbiwmtilhmmbin Ill co&e:: 
mce”trii& between patients with md whhotn rem&m 
angina (Table 4) likewise impliiates the involvement of 
platelet-aswciated mediators including thmmboaaae A,, 
newtonin. platelet activatiag Cactor, a&n&e diphosphatc 
and lcukottienes in the pathogencsis of recurrent unstable 
angina alter argatroban inlusion (41,421. 
clhial bnplkatimM oftbs s&dy. Proposed mechanisms 
for the rebound in viva coagulation aCter cessation of hepwin 
infusion included the release of thmmbin from the hepa& 
antithmmbin~thrombin complex or from fibrin or a reduction 
of antithrombin 111 levels durina hetwin inCusion with aa 
associated hypcrco.qulable stat; (i. However, “one of 
these mechanisms would explain the rebound coagulation 
in the present study. A possible mcchanis~might consist of 
reduction of the lhrombin-lhmmbomodulin complex at the 
cndotheliat surface resulting in reduced activation of protein 
C, which might predispose to a lhrombolic tendency (43). 
Whatever the cause of the rebound phenomenon after anti- 
coagulant withdrawal, its mere exisience may have signifi- 
cant implications for the use of anticoagulants in the man- 
agement of ischemic coronary syndromes. The elucidation 
of its mechanism and temporal evolution may allow opti- 
mized tnalmerd of thromboembolic disease with poten! 
specitk thrombin inhibitors. 

